ISRCTN72968188已完成未知
Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after a three-year follow-up
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro0 个研究点目标入组 65 人开始时间: 2021年7月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 65
研究概览
简要总结
2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34325685/ (added 02/08/2021)
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Aged = 18 years
- •2.Systemic sclerosis diagnosis according to the 2013 European League Against Rheumatism and American College of Rheumatology criteria
排除标准
- •1. Severe left ventricle dysfunction (left ventricular fraction ejection <55%)
- •2. Severe restrictive lung disease (forced vital capacity <40%)
- •3. Unwillingness to undergo right heart catheterization
研究者
相似试验
已完成
2 期
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)Systemic Sclerosis-Associated PAHNCT01086540National Institute of Allergy and Infectious Diseases (NIAID)57
Unknown
不适用
Development and Prevention of Pulmonary Hypertension in Systemic SclerosisPulmonary HypertensionSystemic SclerosisNCT01840748University of Paris 5 - Rene Descartes960
已完成
不适用
Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary HypertensionPulmonary HypertensionNCT01729611The Cleveland Clinic119
招募中
不适用
Pulmonary manifestation in systemic sclerosis in Srinagarind HospitalHRCT findingSclerosisPulmonary manifestationSclerodermaTCTR20150422001MDResearch.kku300
进行中（未招募）
不适用
Treatment of Pulmonary Hypertension and Sickle Cell Disease with Sildenafil Therapy - Walk PHaSSTEUCTR2007-000446-12-GBImperial College London132